ASN guidance on CKM syndrome: use PREVENT risk equations in CKD; RAS and SGLT2 inhibitors are foundational, with GLP-1 therapies and nonsteroidal MRAs added by risk, plus lipid management. Evidence is limited in dialysis, transplant, GN, children, frailty.
Guideline
Navaneethan et al. Executive Summary of the ASN Kidney Health Guidance on the Cardiovascular‑Kidney‑Metabolic Syndrome